Black Diamond Therapeutics Inc Ordinary Shares BDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDTX is a good fit for your portfolio.
News
-
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Black Diamond Therapeutics Announces Changes to Board of Directors
-
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
-
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
-
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $5.89
- Day Range
- $5.47–6.16
- 52-Week Range
- $1.43–6.85
- Bid/Ask
- $5.60 / $6.20
- Market Cap
- $303.33 Mil
- Volume/Avg
- 3.0 Mil / 654,759
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 54
Comparables
Valuation
|
Metric
|
BDTX
|
PMVP
|
IKNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.59 | 0.40 | 0.38 |
Price/Sales | — | — | 6.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
BDTX
PMVP
IKNA
Financial Strength
|
Metric
|
BDTX
|
PMVP
|
IKNA
|
|---|---|---|---|
Quick Ratio | 6.69 | 14.47 | 12.35 |
Current Ratio | 6.82 | 14.78 | 12.58 |
Interest Coverage | — | — | — |
Quick Ratio
BDTX
PMVP
IKNA
Profitability
|
Metric
|
BDTX
|
PMVP
|
IKNA
|
|---|---|---|---|
Return on Assets (Normalized) | −48.80% | −23.12% | −32.53% |
Return on Equity (Normalized) | −66.24% | −25.57% | −38.49% |
Return on Invested Capital (Normalized) | −54.64% | −27.79% | −36.66% |
Return on Assets
BDTX
PMVP
IKNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mznbgmnytn | Qspy | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lbrvfbpqs | Wnvws | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zykgdrj | Mnzprt | $98.3 Bil | |
MRNA
| Moderna Inc | Vnjtxgvp | Wnbdw | $42.7 Bil | |
ARGX
| argenx SE ADR | Qzlnfxyrf | Qjxbj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Szxzmskp | Mhqn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zghjfmss | Vctgpv | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Khrjpsm | Dqpllq | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zyxyzkbjsm | Vbpmhq | $12.7 Bil | |
INCY
| Incyte Corp | Cssjxqf | Rndydyd | $11.8 Bil |